Related Experiment Video
Updated: Jul 15, 2026
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
SF3a1: A Novel Potential Tumor Biomarker or Therapeutic Target
Xueqian Shuai1, Yaoqi Sun1, Shupeng Liu2
1Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200040, China.
Abstract:
Alternative splicing is an evolutionarily conserved and essential cellular process that is catalyzed by a multi-complex spliceosome. Dysregulation of this process has been implicated in various tumors over the recent years. SF3a1 is a critical subunit of U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome, which has been found to be aberrant in several human diseases. Recent reports suggest that SF3a1 might be a novel therapeutic target. However, a comprehensive description of SF3a1 is lacking. In this review, we present the findings of SF3a1 from protein structure, biological function to strong associations with human diseases including cancer. Studies have reported that SF3a1 dysregulation and associated alternative splicing events mediate tumorigenesis and other immune-related disorders. However, further functional and mechanistic studies are needed to fully understand the regulatory network of SF3a1 in human diseases. In conclusion, SF3a1 could serve as a promising prognostic biomarker and therapeutic target for specific cancer types, including prostate cancer, colorectal cancer and hepatocellular carcinoma.
Insights
SF3a1, a spliceosome component, is crucial in alternative splicing and implicated in various cancers. Its dysregulation links to tumorigenesis, suggesting SF3a1 as a potential therapeutic target and biomarker.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Alternative splicing, a fundamental cellular process, is catalyzed by the spliceosome.
- Dysregulation of alternative splicing is increasingly linked to various human cancers.
- SF3a1, a key subunit of the U2 small nuclear ribonucleoprotein (snRNP) complex within the spliceosome, has been identified as aberrant in numerous diseases.
Purpose of the Study:
- To provide a comprehensive review of SF3a1, covering its protein structure, biological functions, and disease associations.
- To highlight the role of SF3a1 dysregulation in mediating tumorigenesis and immune-related disorders.
- To evaluate SF3a1 as a potential prognostic biomarker and therapeutic target in oncology.
Main Methods:
- Literature review synthesizing findings on SF3a1.
- Analysis of studies linking SF3a1 to alternative splicing and disease pathogenesis.
- Examination of SF3a1's role in cancer development and progression.
Main Results:
- SF3a1 is essential for spliceosome function and its aberrant expression is observed in various human diseases, including cancers.
- SF3a1 dysregulation contributes to tumorigenesis through altered alternative splicing events.
- SF3a1 has demonstrated strong associations with diseases such as prostate cancer, colorectal cancer, and hepatocellular carcinoma.
Conclusions:
- SF3a1 plays a critical role in alternative splicing and its dysregulation is implicated in cancer.
- Further research into SF3a1's regulatory network is necessary for a complete understanding of its role in human diseases.
- SF3a1 holds promise as a prognostic biomarker and therapeutic target for specific cancer types.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
